The contribution of marker gene studies to hemopoietic stem cell therapies
Open Access
- 1 January 1995
- journal article
- review article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 13 (5) , 453-461
- https://doi.org/10.1002/stem.5530130502
Abstract
Although the transfer of “therapeutic” genes into hemopoietic stem cells (HSC) offers many opportunities to treat a wide range of human disease, the low efficiency of transfer and limited expression of the transferred gene have so far largely prevented any direct beneficial effect from being obtained. However, gene marker studies in which the transferred genes are used simply to track the individual components of the infused HSC have already shown their utility. Genetic marking may be used to identify cells capable of causing relapse after autologous bone marrow transplantation and to distinguish cells in the graft capable of preventing malignant disease. Marking may also be used to analyze the consequences of ex vivo or in vivo manipulations of the HSC which are intended to accelerate engraftment or augment gene transfer efficiencies. Information obtained from these studies should therefore not only improve the outcome of HSC based therapies, but also aid in the introduction of successful gene therapy protocols.Keywords
This publication has 39 references indexed in Scilit:
- Donor T Cells to Treat EBV-Associated LymphomaNew England Journal of Medicine, 1994
- Bone marrow extracellular matrix molecules improve gene transfer into human hematopoietic cells via retroviral vectors.Journal of Clinical Investigation, 1994
- Use of Marker Genes to Investigate the Mechanism of Relapse and the Effect of Bone Marrow Purging in Autologous Transplantation for Stage D Neuroblastoma. St. Jude Children's Research HospitalHuman Gene Therapy, 1993
- Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer.The Journal of Experimental Medicine, 1992
- Selection of Drug-Resistant Bone Marrow Cells in Vivo After Retroviral Transfer of Human MDR 1Science, 1992
- Autologous bone marrow transplantation in solid tumorsCurrent Opinion in Oncology, 1992
- Autologous Bone Marrow Transplantation for CML in Which Retroviral Markers Are Used to Discriminate Between Relapse Which Arises from Systemic Disease Remaining after Preparative Therapy Versus Relapse due to Residual Leukemia Cells in Autologous Marrow: A Pilot Trial. The University of Texas M.D. Anderson Cancer CenterHuman Gene Therapy, 1991
- Graft-versus-host reactions and bone-marrow transplantationCurrent Opinion in Immunology, 1991
- Erythropoietin for the Treatment of Porphyria Cutanea Tarda in a Patient on Long-Term HemodialysisNew England Journal of Medicine, 1990
- Autologous Bone Marrow Transplantation in Patients with Acute Nonlymphocytic Leukemia, Using ex Vivo Marrow Treatment with 4-HydroperoxycyclophosphamideNew England Journal of Medicine, 1986